Intra-Cellular Therapies, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ITCI research report →
About the company
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States.
- CEO
- Sharon Mates
- IPO
- 2014
- Employees
- 860
- HQ
- New York City, NY, US
Price Chart
- Market Cap
- $14.05B
- P/E
- -183.15
- P/S
- 20.63
- P/B
- 11.84
- EV/EBITDA
- -117.86
- Div Yield
- 0.00%
- Gross Margin
- 91.63%
- Op Margin
- -17.14%
- Net Margin
- -10.97%
- ROE
- -8.58%
- ROIC
- -9.98%
- Revenue
- $680.85M · 46.62%
- Net Income
- $-74,676,000 · 46.54%
- EPS
- $-0.72 · 50.68%
- Op Income
- $-116,721,000
- FCF YoY
- 40.95%
- 52W High
- $131.98
- 52W Low
- $64.09
- 50D MA
- $129.42
- 200D MA
- $92.67
- Beta
- 0.46
- Avg Volume
- 3.62M
Get TickerSpark's AI analysis on ITCI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 2, 25 | Salas Eduardo Rene | sell | 20,000 |
| Apr 2, 25 | Salas Eduardo Rene | sell | 16,757 |
| Apr 2, 25 | Salas Eduardo Rene | sell | 4,322 |
| Apr 2, 25 | Salas Eduardo Rene | sell | 1,567 |
| Apr 2, 25 | Salas Eduardo Rene | sell | 7,009 |
| Apr 2, 25 | Salas Eduardo Rene | sell | 2,951 |
| Apr 2, 25 | RIGGS RORY B | sell | 7,009 |
| Apr 2, 25 | RIGGS RORY B | sell | 20,000 |
| Apr 2, 25 | RIGGS RORY B | sell | 20,000 |
| Apr 2, 25 | RIGGS RORY B | sell | 20,000 |
Our ITCI coverage
Recent articles, reports, and earnings notes.
No research on ITCI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ITCI report →Similar companies
Peers in the same neighborhood.